JPRN-UMIN000006823已完成2 期
Phase II study of S-1 plus irinotecan combined with biweekly cetuximab as 2nd-line chemotherapy in patients with wild type KRAS unresectable colorectal cancer, who had previously received oxaliplatin-based chemoterapy without CV port. (FUTURE 1103 STUDY) - Phase II study of S-1 plus irinotecan combined with biweekly cetuximab as 2nd-line chemotherapy in patients with wild type KRAS unresectable colorectal cancer, who had previously received oxaliplatin-based chemoterapy without CV port. (FUTURE 1103 STUDY)
Fukuoka Tumor Research(FUTURE)0 个研究点目标入组 30 人开始时间: 2011年12月3日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) History of severe allergy 2) Simultaneous or metachronous double cancers 3) Symptomatic brain metastasis 4) Severe infectious disease 5) Severe complications (interstitial lung disease or pulmonary fibrosis, heart failure, kidney failure, hepatic failure, uncontrolable diabetes, Jaundice) 6) Paralytic or mechanical bowel obstruction 7) Massive pleural effusion or ascites 8) Wattery diarrhea 9) Patients who is receiving Atazanavir Sulfate or Flucytosine 10) Pregnant or lactating women or women of childbearing potential 11) Any other cases who are regarded as inadequate for study enrollment by the investigator.
研究者
相似试验
已完成
2 期
Phase II study of S-1 plus irinotecan combined with bevacizumab as 2nd-line chemotherapy in patients with unresectable colorectal cancer, who had previously received oxaliplatin-based chemotherapy.Colorectal cancerJPRN-UMIN000006307Kyushu Study group of Clinical Cancer37
已完成
不适用
Phase II study of S-1 combined with irinotecan in patients with advanced colorectal cancerJPRN-UMIN000001741Showa University School of Medicin40
已完成
2 期
Multicenter Phase II trial of Irinotecan plus S-1 with cetuximab (IRIS/Cet) in patients with EGFR positive and KRAS wild type of advanced/metastatic colorectal canceradvanced/metastatic colorectal cancerJPRN-UMIN000004882PO Hokkaido Gastrointestinal Cancer Study Group (HGCSG)80
已完成
2 期
A Phase II trial of irinotecan / S-1 (IRIS) + alfa (Panitumumab/Bevacizumab) as 2nd line chemotherapy for metastatic colorectal cancer (mCRC) A multicenter phase II trial of TS1 + Irinotecan (IRIS) + Panitumumab as second line treatment in patients with KRAS wild type unresectable advanced colorectal cancer (mCRC).metastatic colorectal cancerJPRN-UMIN000009317Yamaguchi University Department of Digestive Surgery and Surgical Oncology30
已完成
2 期
A Phase II trial of irinotecan / S-1 (IRIS) + alfa (Panitumumab/Bevacizumab) as 2nd line chemotherapy for metastatic colorectal cancer (mCRC) A multicenter phase II trial of TS1 + Irinotecan (IRIS) + Bevacizumab as second line treatment in patients with KRAS mutant type unresectable advanced colorectal cancer (mCRC).metastatic colorectal cancerJPRN-UMIN000009318Yamaguchi University Department of Digestive Surgery and Surgical Oncology30